Angiopoietin and Adverse Outcomes in Cardiac Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

blood sample: 5 ml blood sample will be withdrawn at the surgery start and at the surgery end

Study summary

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.

The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Eligibility

Primary outcome measure(s)

• Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event — 28 days
  major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
• correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event — 28 days
  major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

Trial sites (1)

More Centre Hospitalier Universitaire, Amiens trials in France

Other trials for the same condition